Publications by authors named "Werner Engl"

Claim this Profile
I
Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.
Frank M Horling, Birgit M Reipert, Peter Allacher, Werner Engl, Luying Pan

Blood Adv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial.
Tina Manon-Jensen, Srilatha Tangada, Cecilie Bager, Pratima Chowdary, Robert Klamroth, Werner Engl

J Thromb Haemost· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
Robert F Sidonio, Alexis A Thompson, Flora Peyvandi, Oleksandra Stasyshyn, Seoh Leng Yeoh, Werner Engl

Expert Rev Hematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: subanalysis of the randomized, phase 3 PROPEL study.
Carmen Escuriola-Ettingshausen, Robert Klamroth, Miguel Escobar, Oleksandra Stasyshyn, Srilatha Tangada, Werner Engl

Ther Adv Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases.
Richard L Wasserman, Sudhir Gupta, Mark Stein, Christopher J Rabbat, Werner Engl

Immunotherapy· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
Zhaoyang Li, Barbara McCoy, Werner Engl, Leman Yel

J Clin Immunol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery.
Ingrid Pabinger, Vasily Mamonov, Jerzy Windyga, Werner Engl, Jennifer Doralt

Haemophilia· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.
Robert Klamroth, Jerzy Windyga, Vlad Radulescu, Peter W Collins, Oleksandra Stasyshyn, Werner Engl

Blood· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing goodness-of-fit for evaluation of dose-proportionality.
Martin J Wolfsegger, Alexander Bauer, Detlew Labes, Helmut Schütz, Richardus Vonk, Werner Engl

Pharm Stat· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
Yongqiang Zhao, Yu Hu, Jie Jin, Xielan Zhao, Xuefeng Wang, Werner Engl

Clin Appl Thromb Hemost· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Pratima Chowdary, Eric S Mullins, Barbara A Konkle, Catherine McGuinn, Young Shil Park, Werner Engl

Haemophilia· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A.
Jayashree Motwani, Benoit Guillet, Jan Blatny, Freimut H Schilling, Bénédicte Wibaut, Werner Engl

Haemophilia· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
Pratima Chowdary, Kathelijn Fischer, Peter W Collins, Amy Cotterill, Barbara A Konkle, Werner Engl

Thromb Haemost· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases.
Sudhir Gupta, Mark Stein, Iftikhar Hussain, Kenneth Paris, Werner Engl

Ann Allergy Asthma Immunol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Ralph Gruppo, Maria-Fernanda López-Fernández, Tung T Wynn, Werner Engl, Marlies Sharkhawy

Haemophilia· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.
Chur Woo You, Hee Jo Baek, Sang Kyu Park, Young Shil Park, Ho-Jin Shin, Werner Engl

Blood Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents.
Daniel Suez, Gergely Kriván, Stephen Jolles, Mark Stein, Sudhir Gupta, Werner Engl

Immunotherapy· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies.
Kenneth Paris, Elie Haddad, Michael Borte, Nicholas Brodszki, Beáta Dérfalvi, Werner Engl

Immunotherapy· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitor development, safety and efficacy of Advate among previously treated patients with hemophilia A in a postmarketing surveillance in Japan.
Katsuyuki Fukutake, Masashi Taki, Tadashi Matsushita, Keiji Nogami, Midori Shima, Werner Engl

Int J Hematol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.
Masashi Taki, Katsuyuki Fukutake, Tadashi Matsushita, Keiji Nogami, Midori Shima, Werner Engl

Int J Hematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitor development, safety, and efficacy of Advate in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.
Masashi Taki, Katsuyuki Fukutake, Tadashi Matsushita, Keiji Nogami, Midori Shima, Werner Engl

Int J Hematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative safety and hemostatic efficacy of Advate in patients with hemophilia A in a postmarketing surveillance in Japan.
Keiji Nogami, Hideyuki Takedani, Midori Shima, Akira Yoshioka, Tadashi Matsushita, Werner Engl

Int J Hematol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Keiji Nogami, Midori Shima, Katsuyuki Fukutake, Teruhisa Fujii, Masashi Taki, Werner Engl

Int J Hematol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Keiji Nogami, Midori Shima, Katsuyuki Fukutake, Teruhisa Fujii, Masashi Taki, Werner Engl

Int J Hematol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
Richard L Wasserman, Isaac Melamed, Lisa Kobrynski, Jennifer Puck, Sudhir Gupta, Werner Engl

Immunotherapy· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis